Cantargia Ab · OMXSTO:CANTA
Cantargia Ab — Q1 2025 Earnings Presentation
31 slides from Cantargia Ab's earnings presentation, May 13, 2025
Slide 1: Corporate Presentation June 2025
Blocking the 2)GH7 signals to reduce disease s Corporate Presentation June 2025 NASDAQ STOCKHOLM MAIN LIST (CANTA.ST)
Slide 2: Safe Harbor Statement
Safe Harbor Statement Statements in the Investor Presentation, including those regarding the possible or assumed future or other performance of the Company or its industry or other trend projections, constitute forward-looking statements. By their nature, forward-looking statements involve known and
Slide 3: Cantargia — Global leader in IL1RAP antibody development
Cantargia — Global leader in IL1RAP antibody development NOVEL IL1RAP ANTIBODIES: BROADLY APPLICABLE TO TREAT INFLAMMATORY DISEASES & CANCER ( oe * IL1RAP signaling drives various autoimmune and inflammatory diseases « IL1RAP elevated in most solid and liquid tumors CAN10: OPPORTUNITY IN AUTOIMMUNIT
Slide 4: Clinical Programs supported by Unique Platform
Clinical Programs supported by Unique Platform Asset Indication Discovery Preclinical Phase 1 Phase 2 Phase 3 Hidradenitis Suppurativa (HS) CAN10 Atopic Dermatitis (AD)* New development programs CANxx through unique IL1RAP platform (e.g. BsMAb, ADC) . PDAC*** PDAC - pancreatic cancer; TNBC - triple-
Slide 5: Executive Management Team
Executive Management Team Damian Marron CEO ~ Patrik Renblad CFO Ton Berkien CBO co} poe § Astrazeneca 2 . LE Oo novo nordisk AMGEN GSK fe Morten Lind Jensen CMO *Genmab FERRING PHARMACEUTICALS: W David Liberg cso 1 -mAbs Therapeutics, Inc. SyYNACT PHARMA nicox © visible science @antargia
Slide 6: CAN10 opportunities in autoimmune/inflammatory diseases
CAN10 OPPORTUNITIES INAUTOIMMUNE/INFLAMMATORY DISEASES = ___CAN10 is an Anti-IL1RAP antibody for treatment of autoimmune and inflammatory disease. CAN10 can, by binding IL1RAP, block IL-1, IL-33 and IL-36 signaling pathways simultaneously. This unique function provides CAN10 with great potential for
Slide 7: CAN10 provides a unique opportunity to block IL-1 superfamily signaling
CAN10 provides a unique opportunity to block IL-1 super- family signaling Joints * — Osteoarthritis Rheumatoid arthritis . . Gout ° The IL-1superfamily of ligands and receptors is primarily associated with - : acute and chronic inflammation’ — Intestine * Hidradenitis Crohn's disease * Strong eviden
Slide 8: CAN10 is developed to block IL-1 superfamily with precision
CAN10 is developed to block IL-1 superfamily with precision IL-1 receptor complex: 1L-33 receptor complex 1L-36 receptor complex ILLRAP/ILAR3 cao MERE cn 2 ao bere ° CAN10 blocks multiple IL-1 family signaling by iS targeting a single receptor —— — Binds crucial epitope on common accessory protein (
Slide 9: CAN10 First-in-Human study (FIH) - SAD/MAD
CAN10 First-in-Human study (FIH) - SAD/MAD SAD (IV) ° Healthy volunteers (N=76) e Placebo controlled * 10 dose cohorts ° Finalized ) MAD — Healthy (SC) & ° Healthy volunteers * Q2 2025: Phase 1 * 2dose cohorts, placebo controlled ° SC Day 1, 7 followed by every 14 days ° Phase 2 preparations MAD -—
Slide 10: CAN10 saturates IL1RAP on monocytes and neutrophils
10 CAN10 FIH - CAN10 saturates IL1RAP on monocytes and neutrophils ° Receptor occupancy documented (at C,,,,) * Full IL1RAP coverage from 25-50 mg single dose IV Classical monocytes 80. 0 2 60 2° R40 20 ° lomo) — 0 ° T T T T T T T T T T T EOS oe Neutrophils @antargia
Slide 11: CAN10 FIH - Full blockade of both IL-36 and IL-1B signaling
CAN10 FIH - Full blockade of both IL-36 and IL-18 signaling ° Inhibition of IL-36 and IL-1 signaling documented at C, days after 3 dose (MAD) > long lasting effect IL-36 inhibition Ratio to stimulated baseline IL-36 induced IL-6 release Cmax (SAD and MAD) Ratio to stimulated baseline IL-36 induced I
Slide 12: CAN10 FIH - PK results support Q4W dosing
CAN10 FIH - PK results support Q4W dosing Linear PK profile High bioavailability PK model development has been performed by Certara Results from simulations support feasibility of Q4W dosing Lowest estimated level for efficacy (Crrough) has been set based on ex vivo inhibition assay results and RO 0
Slide 13: Hidradenitis Suppurativa (HS) — Disease Overview
Hidradenitis Suppurativa (HS) —- Disease Overview 60 million people Of people worldwide have Hidradenitis = Suppurativa Of patients moderate/severe HS (Hurley stage —) I/II) ___|srace mt (severe) Of HS Patients are not well controlled = on Standard Of Care ee Time that patients suffer from symptoms
Slide 14: Despite advances in HS, new approaches are needed
Despite advances in HS, new approaches are needed to break the efficacy ceiling, improve convenience and safety 80 5 = S 604 wo a 3 x= sonelokimab Cantargia 3 40 fo NX IL1RAP a 2 bimzelx S A 3 lutikizumab g 24 humira s o 5 spevigo povorcinib casentyx: 0 T T T T T T 1 ie} 1 2 3 4 5 6 7 Maintenance do
Slide 15: Unique MoA in the treatment of HS
Unique MoA in the treatment of HS IL-1 superfamily has roles integrated with and in parallel to the IL-17 pathway • IL-1 superfamily cytokines are jointly upregulated in HS skin lesions “Lutikizumab functionality” “Spesolimab functionality” • Unique CAN10 MoA differentiates from current treatments a
Slide 16: CAN10 is validated by external clinical results in HS
CAN10 is validated by external clinical results in HS Spesolimab Spesolimab e 100-) 105 IL-36R-blockade (spesolimab) positive results on disease severity’ 5, so gS ° Efficacy in Phase 2 randomized controlled study: iHS4 and HASI-R, if rf ° with a particular effect on draining tunnels (dTs) BE 6 yl 2
Slide 17: Next: Proposed Phase 2 study in HS
Next: Proposed Phase 2 study in HS (— Safety and tolerability XN CAN10 dose 1 * N=~40 pts per active arm, CAN10 dose 2 Boerne on N =~40-60 in placebo number of patients Placebo previously failing TNFa or IL-17 blockade 16 weeks * ~50 EU/US sites Ne Primary Endpoint (e: ient lation Primary Endpoint e
Slide 18: Atopic Dermatitis (AD) - Disease Overview & Treatment Approach
Atopic Dermatitis (AD) - Disease Overview & Treatment Approach ~ 46 million’ Prevalent diagnosed patient population of people suffering from AD Expected global sales in AD treated population in 2033 Even among patients treated with the most prescribed biologic for AD, dupilumab, ~ 30% have inadequat
Slide 19: CAN10 rationale in AD patients not responding to dupilumab
19 CAN10 rationale in AD patients not responding to dupilumab ° Broad activation of inflammatory pathways in AD ° IL-1, IL-33 and IL-36 affects several of the inflammatory pathways implicated in AD * Clinical data and commercial interest indicating benefit of individual cytokine blockade ° Signs of
Slide 20: Non-clinical data supporting CAN10 in AD
Non-clinical data supporting CAN10 in AD ° Multiple pathways and signaling levels targeted simultaneously » MOA supported by results from several non-clinical activities e Reduces IL-17, IL-5 ° Blocks tissue inflammation superior to IL-1 blockade (including skin) * Blocks IL-1/33-induced endothelial
Slide 21: Nadunolimab
NADUNOLIMAB COMBAT CANCER AND ENHANCE THE IMMUNE SYSTEM'S ABILITY TO DESTROY CANCER CELLS a Nadunolimab (CANO4) is an Anti-IL1RAP antibody for treatment of various cancer types. CAN04 binds strongly to its target molecule IL1RAP, expressed on tumor cells from many types of cancer. CAN04 blocks the s
Slide 22: IL1RAP overexpressed in most solid tumors
IL1RAP overexpressed in most solid tumors provides treatment opportunity in various cancer types IL1RAP EXPRESSION IN SOLID TUMOR TYPES INCIDENCE RATES SHOW BROAD OPPORTUNITY IN VARIOUS CANCER TYPES 100% IL1RAP-expressing tumors 75% 50% 25% 0% C l C st al ic er er ta SC CL at ge ea Liv d ec ad re NS
Slide 23: High IL1RAP expression is linked to poor outcome in pancreatic tumors
High IL1RAP expression is linked to poor outcome in patients with pancreatic tumors → IL1 family members are upregulated in PDAC tumors as compared to normal pancreatic tissue → IL1RAP is expressed on tumor cells, cancer- associated fibroblasts and immune cells in tumor microenvironment Protein Atla
Slide 24: PDAC - Strong efficacy in patients with high tumor IL1RAP expression
PDAC - Strong efficacy in patients with high tumor IL1RAP expression level OS by IL1RAP subgroup IL1RAP High IL1RAP Low Efficacy analysis for IL1RAP High (n=29) vs IL1RAP Low (n=20) PDAC patients → High IL1RAP expression is a poor prognostic marker for treatment with gem/nab-paclitaxel → Significant
Slide 25: PDAC – Manageable safety with a potential benefit
PDAC – Manageable safety with a potential benefit → Neutropenia manageable through G-CSF prophylaxis → In 6 patients given G-CSF prophylaxis, none developed grade 3-4 neutropenia → Only 1 % peripheral neuropathy grade 3-4 observed (17% in historical controls) Gem/Abraxane Nadunolimab+Gem/Abraxane G
Slide 26: PDAC – Next steps
PDAC – Next steps IL1RAP Assay Feasibility Proposed PDAC study design Assay development; selection of one clone, one platform and one protocol • Metastatic PDAC patients selected for high IL1RAP expression • Treatment naive patients Validation • Combination with gemcitabine/nab- Assay validation; en
Slide 27: Triple-negative breast cancer (TNBC)
Triple-negative breast cancer (TNBC) Promising early safety and efficacy 3 8 8 g -50% Best change in tumor size f=} =e -100% Best responses according to RECIST sD PR mR 100% 75% 50% 25% Survival probability 0% OS and PFS ~ PFS Benchmark Gem/Carbo: OS 11.1 mo, PFS 4.1 mo, ORR 30% (O’Shaughnessy et al
Slide 28: Milestones & Investment Highlights
MILESTONES & INVESTMENT HIGHLIGHTS
Slide 29: Upcoming Milestones
Upcoming Milestones 2025 Q1 Q2 Q3 Q4 Initial Phase 1 Phase 1 MAD study Phase 2 start CAN10 MAD results () completed in HS & AD PDAC Regulatory Update a TRIFOUR recruitmei TRIFOUR initial Nadunolimab TNBG completed re) results Study start with AML MD Anderson* (2) Other Additional new preclinical and
Slide 30: Investment Highlights
Investment Highlights CORPORATE STRENGTH DRIVING INNOVATION • Dedicated Team with experience from Pharma, Biotech & Academia • Two clinical programs ongoing: CAN10 and nadunolimab • CANxx Technology Platform (ADC + Bi-Specific mAb): Worldclass Leader in IL1RAP antibody development CAN10: STRONG PHAS
Slide 31: Thank you
(oantargia Thank you Contact details: Damian Marron Chief Executive Officer Patrik Renblad Chief Financial Officer